Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.
Md Yuzaiful Md Yusof, British Society for Rheumatology Guidelines Steering Group members, Liz Lightstone(Imperial College London), Bridget Griffiths(Freeman Hospital), Edward M Vital(University of Leeds), Nadia Corp, Daniëlle van der Windt, Lambert Felix, Philip Laws(Leeds Teaching Hospitals NHS Trust), Christian Mallen(Keele University), Rebecca Gilman(University of Birmingham), Heather Rostron(University of Leeds), Antonios Psarras(Nuffield Orthopaedic Centre), Dalila Tremarias(LUPUS UK), Jade Skeates(Royal National Hospital for Rheumatic Diseases), Elena Moraitis(Great Ormond Street Hospital), Hanna Lythgoe(Manchester University NHS Foundation Trust), Sarah Skeoch(Royal National Hospital for Rheumatic Diseases), Clare Nash(Sheffield Children's NHS Foundation Trust), Kalveer Flora(London North West Healthcare NHS Trust), Chris Wincup(King's College Hospital), Debbie Kinsey, Ruth J. Pepper(University College Hospital), Zoe McLaren, Peter Lanyon, Clarissa Pilkington, Asad Zoma, Natasha Jordan, Lindsey Cherry, Caroline Gordon, Kate Armon, Christopher J Edwards, Eve MD Smith, Stephen D Marks, David Isenberg, Michael W Beresford, Naomi Maxwell(LUPUS UK), Arvind Kaul(St George’s University Hospitals NHS Foundation Trust)
Apollo (University of Cambridge)
April 20, 2026
Cited by 0
Related Papers
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478